Journal Article

Immunization with recombinant LiHyp1 protein plus adjuvant is protective against tegumentary leishmaniasis

Ramos, Fernanda F., Martins, Vívian T., Christodoulides, Myron, Pereira, Isabela A.G., Jesus, Marcelo M., Galdino, Alexsandro S., Menezes-Souza, Daniel, Pimenta, Breno L., Duarte, Mariana C., Chávez-Fumagalli, Miguel A., Freitas, Camila S., Roatt, Bruno M., Teixeira, Antônio L., Moreira, Gabriel J.L., Ludolf, Fernanda, Lage, Daniela P., Tavares, Grasiele S.V., Gonçalves, Denise U., Bandeira, Raquel S., Vale, Danniele L., Coelho, Eduardo A.F.

2023

Overview

Tegumentary leishmaniasis (TL) is the main clinical manifestation of leishmaniasis, and it can cause the infected hosts to self-healing cutaneous lesions until mutilating scars in mucosal membranes, particularly in the nose and throat. The treatment against disease presents problems, and the diagnosis is hampered by variable sensitivity and/or specificity of the tests. In this context, the development of prophylactic vaccines could be considered as a strategy to control the disease. Previously, we showed that the recombinant LiHyp1 protein plus adjuvant protected mice from infection with Leishmania infantum , which causes visceral leishmaniasis. In the present study, we tested whether rLiHyp1 could induce protection against infection with L. amazonensis , a parasite species able to cause TL. We immunized BALB/c mice with rLiHyp1 plus saponin (rLiHyp1/S) or incorporated in micelles (rLiHyp1/M) as adjuvants and performed parasitological and immunological evaluations before and after infection. Results showed that after in vitro stimulation from spleen cell cultures using rLiHyp1 or a Leishmania antigenic extract (SLA), rLiHyp1/S and rLiHyp1/M groups developed a Th1-type immune response, which was characterized by high levels of IFN-γ, IL-2, TNF-α and IL-12 cytokines, nitrite, and IgG2a isotype antibodies when compared to values found in the control (saline, saponin, micelles alone) groups, which showed higher levels of anti-SLA IL-4, IL-10, and IgG1 antibodies before and after challenge. In addition, mice receiving rLiHyp1/S or rLiHyp1/M presented significant reductions in the lesion average diameter and parasite load in the infected tissue and internal organs. Blood samples were collected from healthy subjects and TL patients to obtain PBMC cultures, which were in vitro stimulated with rLiHyp1 or SLA, and results showed higher lymphoproliferation and IFN-γ production after stimulus using rLiHyp1, as compared to values found using SLA. These results suggest that rLiHyp1 plus adjuvant was protective against experimental TL and could also be considered for future studies as a vaccine candidate against human disease.

• Publisher: Springer Berlin Heidelberg,Springer,Springer Nature B.V
• Subject: Adjuvants / Animals / Antibodies / Antigens / Biomedical and Life Sciences / Biomedicine / blood / Cytokines / Ethylenediaminetetraacetic acid / Health aspects / human diseases / Immune response / Immunization / Immunoglobulin G / Immunology / Infection / Infections / interleukin-10 / interleukin-12 / interleukin-2 / interleukin-4 / Interleukins / Leishmania infantum / Leishmaniasis / Life sciences / Lymphocytes T / Medical Microbiology / Medical research / Medicine, Experimental / Micelles / Microbiology / nitrites / nose / parasite load / Parasites / Parasitic diseases / Penicillin / Peripheral blood mononuclear cells / Proteins / Protozoa / Saponins / spleen / Tegumentary leishmaniasis / throat / Tumor necrosis factor-α / Vaccines / Visceral leishmaniasis / γ-Interferon